Understanding why some patients don't respond to bee venom allergy treatment
Official title: Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
Run by Medical University of Graz · NCT04259359 · Data updated 2026-11-12
This study looks at why some people with bee venom allergies don't get better with treatment and tries to find out if certain allergens make the treatment less effective.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 266 (estimated) |
| Sponsor | Medical University of Graz Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 3 sites (Graz and 2 other locations) |
| Status | Recruiting |
| Started | May 2, 2019 |
| Main results expected | December 2028 |
| Study ends | March 2029 |
| Registry record updated | October 8, 2026 |
| Trial ID | NCT04259359 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 70 who have a history of severe allergic reactions to bee stings and are starting bee venom immunotherapy.
✕Probably not a fit
Patients who have contraindications to venom immunotherapy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the effectiveness of venom immunotherapy (VIT) for patients with bee venom allergy, focusing on the role of predominant sensitizations to specific bee venom allergens as potential risk factors for treatment failure. The study aims to analyze patients who have experienced systemic anaphylactic reactions to bee stings and are undergoing VIT. By identifying the relationship between allergen sensitization and treatment outcomes, the research seeks to optimize bee venom preparations for better efficacy in future therapies.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with bee venom allergies, enhancing the effectiveness of immunotherapy.
How similar studies have gone: While there is existing research on venom immunotherapy, this specific focus on predominant sensitizations as a risk factor for treatment failure is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Legally competent male and female subjects aged from 18 to 70 years with a history of a systemic anaphylactic sting reaction (≥ grade I according to the classification of Ring and Messmer) after bee stings, who will receive bee venom immunotherapy Exclusion Criteria: * Contraindications to VIT
Where it's running
-
Department of Dermatology and Venerology, Medical University of Graz
Graz, Austria Recruiting -
Elbe Klinikum Buxtehude
Buxtehude, Germany Recruiting -
Hospital Universitario de Castellón
Castellon, Spain Recruiting
Study contacts
- Study coordinator: Gunter J Sturm, MD, PhD
- Email: gunter.sturm@medunigraz.at
- Phone: +4331638580318
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Different forms of IgE in health and disease.
We will test whether different forms of IgE in the blood differ between healthy adults and people with allergies, chronic spontaneous urticaria, recent anaphylaxis, mastocytosis, hereditary alpha tryptasemia, X‑linked agammaglobulinemia, or those undergoing venom/medication desensitization.
-
Long-term effects of jack jumper ant venom immunotherapy
This trial will test whether people who completed 3–6 years of jack jumper ant venom immunotherapy still have protection when given a supervised sting challenge after being off treatment for 18 months to 5 years.
-
Testing B-regulatory Cells as a Marker for Allergen Immunotherapy Response
This study tests whether changes in blood B-regulatory cells can signal successful allergen immunotherapy in adults with pollen, dust mite, or insect venom allergies.
-
Immunotherapy for treating insect venom allergies.
This study is testing a new treatment for people aged 14 and older with insect venom allergies to see if it can safely reduce their allergic reactions in real-life situations.
-
Evaluating the safety of immunotherapy for insect venom allergy
This study is testing the safety of a new treatment for people aged 14 and older with insect venom allergies to see how well it works and if it causes any side effects.
-
Evaluating a new method to identify vespid venom allergy risks
This study is testing a new blood test to see if it can help identify people at risk for severe allergic reactions to wasp and hornet stings without having to actually sting them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.